Preimplantation Genetics Diagnosis (PGD) Market (By Test Type: Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, X-Linked Diseases, And Others; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024

September 2017 | 119 pages | ID: PB75E907312EN
Variant Market Research

Abstracts

Global Preimplantation Genetics Diagnosis (PGD) Market is estimated to reach $140 Million by 2024; growing at a CAGR of 6.2% from 2016 to 2024. Preimplantation genetic diagnosis is a procedure which involves genetic profiling of embryos, so as to reduce the possibility of passing on inherited disorders. It aids in detecting embryos with abnormalities and selects healthy embryo that can be used for implanting in the uterus. It decreases the rate of unprompted abortion and increased the probabilities of delivering genetically healthy baby. It majorly helps couples whose offspring are capable of getting affected by severe mendelian disorders, mitochondrial disorders or structural chromosome abnormalities. Presently, PGD is the only available technique which are used to avoid highly affected embryo before implantation.

The factors driving the global preimplantation genetics diagnosis (PGD) market includes decreasing fertility rate, technological advancements in the field of genetic analysis, rising demand for IVF treatments, increasing commonness of genetic disorders, and risk of affecting genetic disorders in embryos with increasing maternal age. Though, ethical and economic concerns and several government regulations would hinder the growth of the market. Furthermore, technological advancements and untapped markets would provide numerous growth opportunities in the forecast period.

The global preimplantation genetics diagnosis (PGD) is segmented on the basis of test type and geography. Test type is further bifurcated as X-linked diseases, HLA typing, chromosomal abnormalities, gender selection, single gene disorders, aneuploidy, and other test types.

Based on geography, global market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada, and Mexico whereas Europe consist of UK, Germany, France, and others. Asia-Pacific is segmented into India, China, Japan, and others, while RoW is bifurcated into South America, Middle East and Africa.

The key market players include Thermo Fisher Scientific, Inc., Cooper Surgical, Inc., Abbott Laboratories, Agilent Technologies, Inc., Natera, Inc., PerkinElmer, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., PerkinElmer, Inc., and Beijing Genomics Institute (BGI), among others.

THE KEY TAKEAWAYS FROM THE REPORT

• The report will provide detailed analysis of Preimplantation Genetics Diagnosis (PGD) Market with respect to major segments such as test type, and geography
• The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
• Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
• An exhaustive regional analysis of Preimplantation Genetics Diagnosis (PGD) Market has been included in the report
• Profile of the key players in the Preimplantation Genetics Diagnosis (PGD) Market will be provided, which include key financials, product & services, new developments and business strategies

SCOPE OF PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET

Test Type Segments

• X-Linked Diseases
• HLA Typing
• Chromosomal Abnormalities
• Gender Selection
• Single Gene Disorders
• Aneuploidy
• Other Test Types

Geographical Segments

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Others
• Asia Pacific
• India
• China
• Japan
• Others
• RoW
• South America
• Middle East
• Africa

Contents

CHAPTER 1 PREFIX

1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
  1.3.1 Primary Research
  1.3.2 Secondary Research
  1.3.3 In-house Data Modeling

CHAPTER 2 EXECUTIVE SUMMARY


CHAPTER 3 MARKET OUTLINE

3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Market Dynamics
  3.3.1 Drivers
    3.3.1.1 Impact Analysis
  3.3.2 Restraints
    3.3.2.1 Impact Analysis
  3.3.3 Opportunities

CHAPTER 4 PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE: MARKET SIZE AND FORECAST, 2015 – 2024

4.1 Overview
4.2 Gender Selection
  4.2.1 Current Trend and Analysis
  4.2.2 Market Size and Forecast
4.3 Chromosomal Abnormalities
  4.3.1 Current Trend and Analysis
  4.3.2 Market Size and Forecast
4.4 Single Gene Disorders
  4.4.1 Current Trend and Analysis
  4.4.2 Market Size and Forecast
4.5 HLA Typing
  4.5.1 Current Trend and Analysis
  4.5.2 Market Size and Forecast
4.6 Aneuploidy
  4.6.1 Current Trend and Analysis
  4.6.2 Market Size and Forecast
4.7 X-Linked Diseases
  4.7.1 Current Trend and Analysis
  4.7.2 Market Size and Forecast
4.8 Other Test Types
  4.8.1 Current Trend and Analysis
  4.8.2 Market Size and Forecast

CHAPTER 5 PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024

5.1 Overview
5.2 North America
  5.2.1 Current Trend and Analysis
  5.2.2 Market Size and Forecast
  5.2.3 U.S.
    5.2.3.1 Market Size and Forecast
  5.2.4 Canada
    5.2.4.1 Market Size and Forecast
  5.2.5 Mexico
    5.2.5.1 Market Size and Forecast
5.3 Europe
  5.3.1 Current Trend and Analysis
  5.3.2 Market Size and Forecast
  5.3.3 UK
    5.3.3.1 Market Size and Forecast
  5.3.4 Germany
    5.3.4.1 Market Size and Forecast
  5.3.5 France
    5.3.5.1 Market Size and Forecast
  5.3.6 Others
    5.3.6.1 Market Size and Forecast
5.4 Asia-Pacific
  5.4.1 Current Trend and Analysis
  5.4.2 Market Size and Forecast
  5.4.3 India
    5.4.3.1 Market Size and Forecast
  5.4.4 China
    5.4.4.1 Market Size and Forecast
  5.4.5 Japan
    5.4.5.1 Market Size and Forecast
  5.4.6 Others
    5.4.6.1 Market Size and Forecast
5.5 RoW
  5.5.1 Current Trend and Analysis
  5.5.2 Market Size and Forecast
  5.5.3 Middle East
    5.5.3.1 Market Size and Forecast
  5.5.4 South America
    5.5.4.1 Market Size and Forecast
  5.5.5 Africa
    5.5.5.1 Market Size and Forecast

CHAPTER 6 COMPANY PROFILES

6.1 Abbott Laboratories
6.2 Natera, Inc.
6.3 PerkinElmer, Inc.
6.4 Illumina, Inc.
6.5 F. Hoffmann-La Roche AG
6.6 Thermo Fisher Scientific, Inc.
6.7 Agilent Technologies, Inc.
6.8 PerkinElmer, Inc.
6.9 Cooper Surgical, Inc.
6.10 Beijing Genomics Institute (BGI)